National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - Full report

Terry A. Jacobson, Matthew K. Ito, Kevin C. Maki, Carl Edward Orringer, Harold E. Bays, Peter H. Jones, James M. McKenney, Scott M. Grundy, Edward A. Gill, Robert A. Wild, Don P. Wilson, W. Virgil Brown

Research output: Contribution to journalArticle

306 Citations (Scopus)

Abstract

The leadership of the National Lipid Association convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. An Executive Summary of those recommendations was previously published. This document provides support for the recommendations outlined in the Executive Summary. The major conclusions include (1) an elevated level of cholesterol carried by circulating apolipoprotein B-containing lipoproteins (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol [LDL-C], termed atherogenic cholesterol) is a root cause of atherosclerosis, the key underlying process contributing to most clinical atherosclerotic cardiovascular disease (ASCVD) events; (2) reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the extent that atherogenic cholesterol is reduced. This benefit is presumed to result from atherogenic cholesterol lowering through multiple modalities, including lifestyle and drug therapies; (3) the intensity of risk-reduction therapy should generally be adjusted to the patient's absolute risk for an ASCVD event; (4) atherosclerosis is a process that often begins early in life and progresses for decades before resulting a clinical ASCVD event. Therefore, both intermediate-term and long-term or lifetime risk should be considered when assessing the potential benefits and hazards of risk-reduction therapies; (5) for patients in whom lipid-lowering drug therapy is indicated, statin treatment is the primary modality for reducing ASCVD risk; (6) nonlipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure, cigarette smoking, and diabetes mellitus; and (7) the measurement and monitoring of atherogenic cholesterol levels remain an important part of a comprehensive ASCVD prevention strategy.

Original languageEnglish (US)
Pages (from-to)129-169
Number of pages41
JournalJournal of Clinical Lipidology
Volume9
Issue number2
DOIs
StatePublished - Mar 1 2015

Fingerprint

Dyslipidemias
Cardiovascular Diseases
Lipids
Cholesterol
Risk Reduction Behavior
Atherosclerosis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Drug Therapy
Clinical Medicine
Apolipoproteins B
HDL Lipoproteins
Hypercholesterolemia
LDL Cholesterol
Life Style
Consensus
Diabetes Mellitus
Therapeutics
Smoking
Hypertension

Keywords

  • Atherogenic cholesterol
  • Atherosclerotic cardiovascular disease
  • Clinical recommendations
  • Coronary heart disease
  • Dyslipidemia
  • Lipoproteins
  • Low-density lipoprotein cholesterol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

National Lipid Association recommendations for patient-centered management of dyslipidemia : Part 1 - Full report. / Jacobson, Terry A.; Ito, Matthew K.; Maki, Kevin C.; Orringer, Carl Edward; Bays, Harold E.; Jones, Peter H.; McKenney, James M.; Grundy, Scott M.; Gill, Edward A.; Wild, Robert A.; Wilson, Don P.; Brown, W. Virgil.

In: Journal of Clinical Lipidology, Vol. 9, No. 2, 01.03.2015, p. 129-169.

Research output: Contribution to journalArticle

Jacobson, TA, Ito, MK, Maki, KC, Orringer, CE, Bays, HE, Jones, PH, McKenney, JM, Grundy, SM, Gill, EA, Wild, RA, Wilson, DP & Brown, WV 2015, 'National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - Full report', Journal of Clinical Lipidology, vol. 9, no. 2, pp. 129-169. https://doi.org/10.1016/j.jacl.2015.02.003
Jacobson, Terry A. ; Ito, Matthew K. ; Maki, Kevin C. ; Orringer, Carl Edward ; Bays, Harold E. ; Jones, Peter H. ; McKenney, James M. ; Grundy, Scott M. ; Gill, Edward A. ; Wild, Robert A. ; Wilson, Don P. ; Brown, W. Virgil. / National Lipid Association recommendations for patient-centered management of dyslipidemia : Part 1 - Full report. In: Journal of Clinical Lipidology. 2015 ; Vol. 9, No. 2. pp. 129-169.
@article{2f36b1f6af9547bab6eb62ef1914e3a0,
title = "National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - Full report",
abstract = "The leadership of the National Lipid Association convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. An Executive Summary of those recommendations was previously published. This document provides support for the recommendations outlined in the Executive Summary. The major conclusions include (1) an elevated level of cholesterol carried by circulating apolipoprotein B-containing lipoproteins (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol [LDL-C], termed atherogenic cholesterol) is a root cause of atherosclerosis, the key underlying process contributing to most clinical atherosclerotic cardiovascular disease (ASCVD) events; (2) reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the extent that atherogenic cholesterol is reduced. This benefit is presumed to result from atherogenic cholesterol lowering through multiple modalities, including lifestyle and drug therapies; (3) the intensity of risk-reduction therapy should generally be adjusted to the patient's absolute risk for an ASCVD event; (4) atherosclerosis is a process that often begins early in life and progresses for decades before resulting a clinical ASCVD event. Therefore, both intermediate-term and long-term or lifetime risk should be considered when assessing the potential benefits and hazards of risk-reduction therapies; (5) for patients in whom lipid-lowering drug therapy is indicated, statin treatment is the primary modality for reducing ASCVD risk; (6) nonlipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure, cigarette smoking, and diabetes mellitus; and (7) the measurement and monitoring of atherogenic cholesterol levels remain an important part of a comprehensive ASCVD prevention strategy.",
keywords = "Atherogenic cholesterol, Atherosclerotic cardiovascular disease, Clinical recommendations, Coronary heart disease, Dyslipidemia, Lipoproteins, Low-density lipoprotein cholesterol",
author = "Jacobson, {Terry A.} and Ito, {Matthew K.} and Maki, {Kevin C.} and Orringer, {Carl Edward} and Bays, {Harold E.} and Jones, {Peter H.} and McKenney, {James M.} and Grundy, {Scott M.} and Gill, {Edward A.} and Wild, {Robert A.} and Wilson, {Don P.} and Brown, {W. Virgil}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.jacl.2015.02.003",
language = "English (US)",
volume = "9",
pages = "129--169",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - National Lipid Association recommendations for patient-centered management of dyslipidemia

T2 - Part 1 - Full report

AU - Jacobson, Terry A.

AU - Ito, Matthew K.

AU - Maki, Kevin C.

AU - Orringer, Carl Edward

AU - Bays, Harold E.

AU - Jones, Peter H.

AU - McKenney, James M.

AU - Grundy, Scott M.

AU - Gill, Edward A.

AU - Wild, Robert A.

AU - Wilson, Don P.

AU - Brown, W. Virgil

PY - 2015/3/1

Y1 - 2015/3/1

N2 - The leadership of the National Lipid Association convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. An Executive Summary of those recommendations was previously published. This document provides support for the recommendations outlined in the Executive Summary. The major conclusions include (1) an elevated level of cholesterol carried by circulating apolipoprotein B-containing lipoproteins (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol [LDL-C], termed atherogenic cholesterol) is a root cause of atherosclerosis, the key underlying process contributing to most clinical atherosclerotic cardiovascular disease (ASCVD) events; (2) reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the extent that atherogenic cholesterol is reduced. This benefit is presumed to result from atherogenic cholesterol lowering through multiple modalities, including lifestyle and drug therapies; (3) the intensity of risk-reduction therapy should generally be adjusted to the patient's absolute risk for an ASCVD event; (4) atherosclerosis is a process that often begins early in life and progresses for decades before resulting a clinical ASCVD event. Therefore, both intermediate-term and long-term or lifetime risk should be considered when assessing the potential benefits and hazards of risk-reduction therapies; (5) for patients in whom lipid-lowering drug therapy is indicated, statin treatment is the primary modality for reducing ASCVD risk; (6) nonlipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure, cigarette smoking, and diabetes mellitus; and (7) the measurement and monitoring of atherogenic cholesterol levels remain an important part of a comprehensive ASCVD prevention strategy.

AB - The leadership of the National Lipid Association convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. An Executive Summary of those recommendations was previously published. This document provides support for the recommendations outlined in the Executive Summary. The major conclusions include (1) an elevated level of cholesterol carried by circulating apolipoprotein B-containing lipoproteins (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol [LDL-C], termed atherogenic cholesterol) is a root cause of atherosclerosis, the key underlying process contributing to most clinical atherosclerotic cardiovascular disease (ASCVD) events; (2) reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the extent that atherogenic cholesterol is reduced. This benefit is presumed to result from atherogenic cholesterol lowering through multiple modalities, including lifestyle and drug therapies; (3) the intensity of risk-reduction therapy should generally be adjusted to the patient's absolute risk for an ASCVD event; (4) atherosclerosis is a process that often begins early in life and progresses for decades before resulting a clinical ASCVD event. Therefore, both intermediate-term and long-term or lifetime risk should be considered when assessing the potential benefits and hazards of risk-reduction therapies; (5) for patients in whom lipid-lowering drug therapy is indicated, statin treatment is the primary modality for reducing ASCVD risk; (6) nonlipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure, cigarette smoking, and diabetes mellitus; and (7) the measurement and monitoring of atherogenic cholesterol levels remain an important part of a comprehensive ASCVD prevention strategy.

KW - Atherogenic cholesterol

KW - Atherosclerotic cardiovascular disease

KW - Clinical recommendations

KW - Coronary heart disease

KW - Dyslipidemia

KW - Lipoproteins

KW - Low-density lipoprotein cholesterol

UR - http://www.scopus.com/inward/record.url?scp=84928823445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928823445&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2015.02.003

DO - 10.1016/j.jacl.2015.02.003

M3 - Article

C2 - 25911072

AN - SCOPUS:84928823445

VL - 9

SP - 129

EP - 169

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 2

ER -